Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection

Inclusion Criteria: * Males and females 18 to 60 years of age * No evidence of cirrhosis or have liver fibrosis corresponding to Metavir Stages 0 to 3 * Subject's liver disease is stable with ALT values \< 5 X ULN * Serologic evidence of detectable plasma HCV-RNA of ≥ 100,000 IU/ml at screening * Documented HCV Genotype 1 chronic hepatitis C. * Judged to be in good health on the basis of medical history and physical examination * All other hematology and clinical chemistry must be within normal limits or show no clinically significant abnormalities. * Be treatment-naïve or experienced. * For female subjects, must not be pregnant or breastfeeding and must be postmenopausal, surgically sterile, abstinent, or using two proven methods of birth control. * Sexually active male subjects, must be practicing acceptable methods of contraception during the treatment period * Female subjects of childbearing potential must have a negative serum ß-HCG pregnancy test at screening and a negative urine pregnancy test on Day 1 before the first dose of study drugs. * Agree not to participate in other clinical trials for the duration of his/her participation in this clinical trial. Exclusion Criteria: * Be participating in any other clinical studies or have participated in another clinical trial within the last 30 days before study drug administration, or participation in more than 2 drug studies in the last 12 months (exclusive of the current study). * Be actively taking hard illicit drugs within 12 months prior to the screening visit or alcohol. * Have a Child-Pugh score \> than 5. * Have evidence of liver cirrhosis including histological evidence of hepatic cirrhosis on any liver biopsy. * Have any cause of liver disease other than chronic hepatitis C-infection * Active or malignant disease or suspicion or history of malignant disease within five previous years (except for adequately treated basal cell carcinoma). * Have clinically significant electrocardiogram abnormalities and/or cardiovascular dysfunction within the previous 6 months * Have significant renal, pulmonary, gastrointestinal absorption, or neurological diseases, or neoplasia. * Have a history of psychiatric disorders determined by the investigator to contraindicate therapy. * Have uncontrolled Type 1 or Type II diabetes. * Antinuclear antibody titer ≥1:320. * Coinfection with hepatitis B and/or HIV 1 or HIV 2.